Trial of Kuvan in Lesch-Nyhan Disease
|Behavioral Manifestations of Lesch-Nyhan Disease||Drug: sapropterin||Phase 2 Phase 3|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Trial of Kuvan™ (Sapropterin) Treatment in Patients With Lesch Nyhan Disease|
- Clinical responses to be monitored will include frequency and severity of self mutilation episodes, frequency and severity of aggressive acts towards others, and any effect on involuntary movements. [ Time Frame: Periodically during the eight weeks of treatment per patient ]
- Effect of Kuvan on standard chemistries, plasma amino acids, and plasma and urinary catecholamines [ Time Frame: Assessed periodically during treatment ]
10mg/kg Kuvan for 5 days followed by 20mg/kg Kuvan for a total of 60 days
oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
Lesch-Nyhan disease (LND) is an X-linked disorder of purine metabolism which results from mutation in the gene for the enzyme hypoxanthineguanine phosphoribosyltransferase (HPRT); patients have hyperuricemia, gout, urinary tract calculi, and nephropathy which are effectively treated with allopurinol. There is also a syndrome of dystonia, chorea and athetosis, as well as involuntary self mutilative biting and aggression toward their caretakers, for which there is no treatment.
Kuvan™ is a form of tetrahydrobiopterin (BH4), and is approved to help lower the blood levels of phenylalanine in people who have phenylketonuria (PKU). LND patients have been found to have decreased BH4 in the spinal fluid and brain; BH4 is a precursor of dopamine, which has an effect on behavior. In an earlier study Dr Nyhan found that treatment of LND with 5-hydroxytryptophan and carbidopa abolished the self-injurious behavior but was uniformly transient.
This is a single site open-label protocol for eight subjects age 4 years and older with Lesch-Nyhan Disease documented by deficiency of HPRT.
The study involves three study visits to San Diego and one study visit done locally. The first visit will last 13 days, the following visits are single day visits at week 4 and week 8, and the local study visit is a brief outpatient visit at week 6. Physical and neurological exams, videotaping of the patient's interactions with the study staff, and blood and urine collection for laboratory analyses will be performed at each San Diego visit. A family member or caregiver will be asked to complete a short assessment form and report any illness or medication changes. In addition, the study staff will have weekly telephone contact with the family to discuss any behavioral changes or study drug issues.
If the patient's self injurious behavior becomes worse after starting Kuvan the drug will be discontinued and the patient will be followed until the behavior returns to baseline.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00935753
|United States, California|
|UCSD Mitochondrial and Metabolic Disease Center|
|San Diego, California, United States, 92103|
|Principal Investigator:||William L Nyhan, MD, PhD||University of California, San Diego|